Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus. At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum. Furthermore, Duphaston is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol.
Diufaston (10 mg N20)
Dydrogesterone, which is the active substance duphaston - progestogen, an analogue of natural progesterone. Has no estrogen, androgen, corticoid effect. Does not alter thermogenesis, therefore, the presence of ovulation can be established for monitoring basal body temperature. No effect on metabolism. Side effects associated with synthetic progestins, has not. Effective when applied inside. Selectively affects progestin receptors in the endometrium. Causes normal secretory transformation of the endometrium in case of sufficient estrogen saturation. No effect on ovulation of the follicle. Does not have the virilizing and / or masculinization action (including the fetus).
After oral ingestion is rapidly absorbed from the gastrointestinal tract. The maximum concentration in blood after injection is observed after 2 hours. 97% of dydrogesterone binds to blood proteins. Hydroxylated in the liver cells. Elimination of the biotransformation products occurs in the urine (56-79%). 72 hours after a single dose completely eliminated from the body. Not bioaccumulates, not an increase in the concentrations of dydrogesterone in patients with renal insufficiency.
• Proven deficiency of endogenous progesterone (endometriosis, luteal phase insufficiency, habitual fetal loss or threatened abortion, premenstrual syndrome, menstrual irregularities, amenorrhea secondary origin, dysmenorrhea).
• Hormone replacement therapy (surgical castration, including the preserved uterus, menopausal syndrome - is applied when necessary neutralization of the proliferative effect of estrogen on the lining of the uterine cavity in the application of estrogen for HRT).
How to use:
Schemes are for reference purposes. To maximize the therapeutic action is necessary to consider the clinical signs of disease and phase of natural menstrual cycle. The daily dosage is divided into several stages, it is better at regular intervals.
When endometriosis is used with 10 mg dydrogesterone 2.3 p / s (without breaks or from 5 th to the 25 day menstrual cycle).
When infertility progesterone genesis 20 mg / day (2 admission) from 11 th to the 25 day MC inclusive. Course of treatment - 3-6 months. If the patient becomes pregnant - treatment should be continued in a dose which is recommended for habitual pregnancy loss. Dose of dydrogesterone can adjust the cytology of vaginal epithelium (kolpotsitologiya).
Habitual loss of pregnancy and threatened abortion - only used in case of evidence of a deficiency of endogenous progesterone.
When threatened abortion used 40 mg of dydrogesterone as a starting dose of 1 time, then - by 10 mg every 8 hours for 1 week. After that, gradually reducing the dosage. However, the signs of renewal threatened abortion may increase the dose again. You can apply up to 12-20 weeks of pregnancy.
When habitual miscarriage therapy begins when planning pregnancy: 10 mg 2 p / c 11 th to 25 th day of the menstrual cycle. If conception has occurred - the therapy at the same dose is constant, with 20 weeks of pregnancy dose gradually. Clarification of the need to increase or decrease the dosage of dydrogesterone may post kolpotsitologicheskogo study.
When predmestrualnom syndrome (PMS) - 10 mg from 11 th to 25 th day of the menstrual cycle. Duration of treatment - 3-6 months.
If dysmenorrhea - 20 mg / day in 2 divided doses from 5 to 25 day menstrual cycle, for 3-6 months.
An irregular menstrual cycle, caused a short luteal phase, used 20 mg / day in 2 divided doses from 11 th to the 25-day cycle.
When treating amenorrhea is used in combination with estrogen. Apply 10 mg of dydrogesterone, 2 times a day from 11 th to 25 th day of the menstrual cycle while taking ethinyl estradiol 0.05 from 1 to 25 day cycle. Duration of treatment - 3 or more menstrual cycles.
With dysfunctional bleeding apply a dose of 10 mg of 2 P / S, 5-7 days in combination with ethinylestradiol 0.05 mg (this scheme stops the bleeding). For the prevention of use of 10 mg dydrogesterone 2 p / c 11 th to 25 th day of the menstrual cycle, combining with .05 ethinyl estradiol 1 p / sec.
As HRT is used only in combination with estrogen.
With continuous therapy using 10 mg of 14 days each menstrual cycle. Under cyclic application - only in the last 12-14 days of estrogen, 10 mg of 1 p / sec. If necessary (insufficient secretory transformation of endometrium, histologically confirmed by ultrasonography or) increase the dose to 20 mg / day.
Rarely - breakthrough bleeding. In this case, dydrogesterone dose should be increased. Can also be an individual hypersensitivity to the drug.
Contraindicated in certain diseases of the liver (Rotor syndrome and Dubin-Johnson), as well as in the case of individual intolerance of dydrogesterone or other components of the drug.
Not contraindicated in pregnancy. If necessary, the drug during lactation, feeding should be abolished (passes into breast milk).
Interaction with other drugs:
No cases of incompatibility of dydrogesterone with other drugs. Phenobarbital and other inducers of microsomal enzymes of hepatocytes may increase the biotransformation of dydrogesterone in the liver and thereby reduce its clinical efficacy.
No reported cases of overdose dydrogesterone. In case of overdose, use of symptomatic treatment and gastric lavage.
Tablets for oral use.
Stored at a temperature of 0-30 ° C in a place protected from light and reach of children. Do not eat after the expiration date printed on the packaging. Shelf life under the conditions - 5 years. From pharmacies released after being a prescription.
Active ingredient: dydrogesterone 10 mg in 1 tablet.
Supporting components: lactose monohydrate, corn starch, methyl-hydroxy-propyl cellulose, dye white (Opadry Y-1-1000), magnesium stearate, silica colloidal anhydrous.
Combined therapy with estrogen should be used cautiously in patients with kidney failure, heart and vascular diseases, epilepsy, diabetes, migraine.
Dydrogesterone does not change the speed of the psycho-physical reactions in the application - can be driving and complex mechanisms.
If a patient had a history of mention of hepatic dysfunction (jaundice, pregnancy, severe itching during pregnancy) - Use with caution.
Before appointment as a hormone replacement therapy is carried out necessary research. In the future regularly prescribe mammograms.
Before using the drug Duphaston you should consult your doctor. This instruction is given a free transfer and is intended solely for information. For more information, please contact the manufacturer annotations.